Sugi Predict

Sugi Predict / Compounds / SCHEMBL2589885

SCHEMBL2589885

SCHEMBL2589885

N#Cc1cnc(NC(=O)Oc2ccccc2)cn1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 16/20 0.59
▸ KDR P35968 2/20 0.49
▸ GSK3A P49840 2/20 0.49
▸ GSK3B P49841 2/20 0.49
▸ PDPK1 O15530 1/20 0.49
▸ DYRK3 O43781 1/20 0.49
▸ MAP4K4 O95819 1/20 0.49
▸ RET P07949 1/20 0.49
▸ PIM1 P11309 1/20 0.49
▸ CSNK1D P48730 1/20 0.49
▸ CLK2 P49760 1/20 0.49
▸ IRAK1 P51617 1/20 0.49
▸ NEK4 P51957 1/20 0.49
▸ CSNK2A1 P68400 1/20 0.49
▸ CSNK1G2 P78368 1/20 0.49
▸ CAMK2D Q13557 1/20 0.49
▸ DYRK1A Q13627 1/20 0.49
▸ NTRK3 Q16288 1/20 0.49
▸ PIM3 Q86V86 1/20 0.49
▸ MINK1 Q8N4C8 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31125084 1.00 CHEK1 (0.59) CHEK1KDRGSK3AGSK3BPDPK1
SCHEMBL27915310 0.86 CHEK1 (0.50) CHEK1KDRGSK3AGSK3BPDPK1
SCHEMBL2595570 0.82 CCNE1 (0.47) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL4294626 0.81 MEN1 (0.52) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL896642 0.81 ALDH1A1 (0.52) CHEK1ALDH1A1MAPT
SCHEMBL30136739 0.81 ALDH1A1 (0.52) CHEK1ALDH1A1MAPT
SCHEMBL24011576 0.79 ALDH1A1 (0.43) ALDH1A1MAPT
SCHEMBL30288121 0.79 ALDH1A1 (0.43) ALDH1A1MAPT
SCHEMBL305046 0.78 NOTUM (0.52) CCNE1CDK2CDK5ALDH1A1MAPT
SCHEMBL32672056 0.78 NOTUM (0.52) CCNE1CDK2CDK5ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170247341-A1 PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES SENTINEL ONCOLOGY LIMITED (GB) 2017-08-31 — — US disclosed
US-20170247341-A1 PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES SENTINEL ONCOLOGY LIMITED (GB) 2017-08-31 — — US disclosed
US-9630931-B2 Pharmaceutically active pyrazine derivatives SENTINEL ONCOLOGY LIMITED (GB) 2017-04-25 — — US disclosed
US-9630931-B2 Pharmaceutically active pyrazine derivatives SENTINEL ONCOLOGY LIMITED (GB) 2017-04-25 — — US disclosed
EP-2780331-B1 PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES SENTINEL ONCOLOGY LTD (GB) 2016-04-20 — — EP disclosed
EP-2780331-B1 PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES SENTINEL ONCOLOGY LTD (GB) 2016-04-20 — — EP disclosed
US-20140323484-A1 Pharmaceutically Active Pyrazine Derivatives SENTINEL ONCOLOGY LIMITED (GB) 2014-10-30 — — US disclosed
US-20140323484-A1 Pharmaceutically Active Pyrazine Derivatives SENTINEL ONCOLOGY LIMITED (GB) 2014-10-30 — — US disclosed
EP-2780331-A1 PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES Sentinel Oncology Limited (GB) 2014-09-24 — — EP disclosed
US-8716287-B2 Pharmaceutical compounds SENTINEL ONCOLOGY LIMITED (GB) 2014-05-06 — — US disclosed
US-20090270416-A1 N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER SENTINEL ONCOLOGY LIMITED (GB) 2009-10-29 — — US disclosed
US-20090270416-A1 N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER SENTINEL ONCOLOGY LIMITED (GB) 2009-10-29 — — US disclosed
EP-2038257-A1 N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS CHK1 INHIBITORS FOR THE TREATMENT OF CANCER Sentinel Oncology Limited (GB) 2009-03-25 — — EP disclosed
WO-2007144579-A1 N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS CHK1 INHIBITORS FOR THE TREATMENT OF CANCER SENTINEL ONCOLOGY LIMITED (GB) 2007-12-21 — — WO disclosed
WO-2007144579-A1 N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS CHK1 INHIBITORS FOR THE TREATMENT OF CANCER SENTINEL ONCOLOGY LIMITED (GB) 2007-12-21 — — WO disclosed
US-7056925-B2 for example, N-{2-[benzyl(2-hydroxyethyl)amino]-5-bromophenyl)}-N'-(5-cyano-2-pyrazinyl)urea, N-{5-bromo-2-[(2-hydroxy-2-phenylethyl)(methyl)amino]phenyl}-N'-(5-cyano-2-pyrazinyl)urea; anticarcinogenic agents ABBOTT LABORATORIES (US) 2006-06-06 — — US disclosed
EP-1534692-A1 UREA DERIVATIVES AS KINASE INHIBITORS Abbott Laboratories (US) 2005-06-01 — — EP disclosed
US-20040259885-A1 Urea kinase inhibitors ABBVIE INC. 2004-12-23 — — US disclosed
WO-2004014876-A1 UREA DERIVATIVES AS KINASE INHIBITORS ABBOTT LABORATORIES (US) 2004-02-19 — — WO disclosed
US-20040034038-A1 Urea kinase inhibitors ABBOTT LABORATORIES 2004-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040034038-A1 Urea kinase inhibitors UCK2, CMPK1, CDK2 CHEK1 50/4885KDR 3774/4885GSK3A 866/4885
US-20090270416-A1 N-OXIDES OF DIARYLUREA DERIVATIVES AND THEIR USE AS Chk1 INHIBITORS FOR THE TREATMENT OF CANCER CHEK1, CHEK2, CDK1 CHEK1 1/4885KDR 2961/4885GSK3A 110/4885
US-20140323484-A1 Pharmaceutically Active Pyrazine Derivatives PHKG1, PHKG2, PLK2 CHEK1 36/4885KDR 1678/4885GSK3A 1037/4885
US-20040259885-A1 Urea kinase inhibitors UCK2, CMPK1, CDK2 CHEK1 50/4885KDR 3774/4885GSK3A 866/4885
US-20170247341-A1 PHARMACEUTICALLY ACTIVE PYRAZINE DERIVATIVES PHKG1, PHKG2, PEAK1 CHEK1 29/4885KDR 1470/4885GSK3A 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.